Dr. Malley runs a research laboratory with funding from the NIH, PATH and the Bill and Melinda Gates Foundation (BMGF). In collaboration with PATH, Dr. Malley led an international effort for the development of a pneumococcal vaccine for developing countries. In 2014, Dr. Malley and collaborators started Affinivax, a biotechnology company based on a novel technology called MAPS to develop vaccines. Streptococcus pneumoniae is the lead target pursued by Affinivax. A 24-valent pneumococcal MAPS vaccine received breakthrough designation by the US FDA and will soon start in Phase 3 clinical trials. Other targets at Affinivax include Gram-negative infections, Staphylococcus aureus and, more recently, Covid-19. Dr. Malley received his early education at Ecole Active Bilingue in Paris, then a BA from Yale University, MD from Tufts University, and infectious diseases and emergency medicine training at Boston Children’s Hospital. A chance meeting with Dr. Porter Anderson led to his interest in the development of a universal pneumococcal vaccine. Under Dr. Anderson’s mentorship, he shifted his research to the development of novel vaccines. His other activities include attending on the inpatient Infectious Diseases consult service, directing the Travel and Geographic Medicine clinic, while also serving as Chief Scientific Officer at Affinivax.